Vertex Pharmaceuticals Incorporated (VRTX) Nasdaq Global Select
163.43-2.74-1.65%
CloseDecember 18, 2018

News: updated – 19-Dec 05:04


The Upcoming Readout For Proteostasis Is In A Make Or Break Situation18-Dec 04:13(SeekingAlpha)

Recently, Proteostasis Therapeutics ( PTI ) announced that it had formed a partnership with Genetech, a subsidiary of Roche ( RHHBY ), for an undisclosed target using the "proteostasis network" technology. This agreement adds some cash to Proteostasis, which will be used to advance its…

Vertex Pharma’s VX-150 successful in mid-stage neuropathy study18-Dec 09:07(SeekingAlpha)

Results from a Phase 2 clinical trial evaluating Vertex Pharmaceuticals’ (NASDAQ: VRTX ) VX-150 in patients with pain caused by small fiber neuropathy showed a treatment benefit. The study met the primary endpoint of a statistically significant reduction in pain as measured by the chang…

Vertex Announces Positive Phase 2 Data in Third Proof-of-Concept Study with the NaV1.8 Inhibitor VX-15018-Dec 08:30(Business Wire)

-Treatment with the NaV1.8 inhibitor VX-150 showed significant relief of pain in patients with small fiber neuropathy and was generally well tolerated- -Third positive Phase 2 proof-of-concept study for VX-150 further validates the potential role of NaV1.8 inhibition for the treatment …

Credit Suisse sees 18% upside in Abbott in premarket analyst action18-Dec 08:05(SeekingAlpha)

Abbott (NYSE: ABT ) initiated with Outperform rating and $82 (18% upside) price target at Credit Suisse. More news on: Abbott Laboratories, Alnylam Pharmaceuticals, Inc., Baxter International Inc, Healthcare stocks news, Stocks on the move, , Read more …